PLAINSBORO, N.J., Oct. 2, 2015 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it closed the acquisition of the United States rights to Tornier’s Salto Talaris® and Salto Talaris® XT ankle replacement products and Tornier’s Futura™ silastic toe replacement products.
“The addition of the Salto Talaris® enhances our lower extremities product offering and accelerates our entry into the U.S. total ankle replacement market,” said Nick Gallucci, Integra’s Vice President, U.S. Sales Leader, Extremity Reconstruction. “We are also pleased to welcome several key employees who will be joining Integra’s commercial organization.”
Integra expects the contribution to adjusted earnings per share to be immaterial during the first 12 months, given the normal sales transition and expected costs associated with the integration. Integra will provide further information on the expected revenues from the transaction on its third quarter earnings call.
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for caregivers, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com